Literature DB >> 14767538

Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma.

Takehiko Ochiumi1, Shinji Tanaka, Shiro Oka, Toru Hiyama, Masanori Ito, Yasuhiko Kitadai, Ken Haruma, Kazuaki Chayama.   

Abstract

Angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF) are thought to be critical regulators in tumor angiogenesis. We investigated the clinical significance of Ang-2 expression at the deepest invasive tumor site under the influence of VEGF expression in relation to angiogenesis, invasive/metastatic potential, and prognosis of advanced colorectal carcinoma (CRC). One hundred and fifty-two patients who underwent surgical resection for advanced CRC were enrolled in this study. Ang-2 and VEGF expression were examined immunohistochemically. Tumor microvessel density (MVD) was examined by immunohistochemical staining against CD34. Ang-2 and VEGF were expressed at the deepest invasive tumor site in 90 (59.2%) and 64 (42.1%) of 152 lesions, respectively. Patients with Ang-2 expression at the deepest invasive tumor site showed significantly (p<0.01) more frequent poorly histologic grade (71.9%), lymphatic involvement (65.9%), venous involvement (69.1%), lymph node metastasis (75.0%), liver metastasis (80.0%) and advanced disease (Dukes' stage C, 70.2%; stage D, 80.0%) than patients without Ang-2 expression. MVD was not significantly up-regulated by Ang-2 expression alone at the deepest invasive tumor site but was significantly up-regulated by VEGF expression at the deepest invasive tumor site under the positive-Ang-2 condition. In patients treated by curative surgery, patients with tumors showing both positive-Ang-2 and positive-VEGF condition at the deepest invasive tumor site had significantly poorer prognoses than patients with tumors under other conditions. Multivariate analysis with logistic regression for 5-year survival in cases of curative surgery showed that lymph node metastasis, VEGF expression and Ang-2 expression were significant factors to predict poor prognosis. Our results suggest that Ang-2 expression in collaboration with VEGF expression at the deepest invasive tumor site may result in tumor angiogenesis and that these angiogenic factors at the deepest invasive tumor site may be correlated with invasive/malignant potential and prognosis of advanced CRC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767538

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  17 in total

Review 1.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Angiogenic and anti-angiogenic factor gene transcript level quantitation by quantitative real time PCR in patients with hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Yogesh Kumar Chawla; Anuradha Chakraborti; Nitin Saini; Ajay Duseja; Ashim Das; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

3.  Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.

Authors:  Zhong-Lin Zhang; Zhi-Su Liu; Quan Sun
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

4.  Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway.

Authors:  Bo Hu; Michael J Jarzynka; Ping Guo; Yorihisha Imanishi; David D Schlaepfer; Shi-Yuan Cheng
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Chemical generation of bispecific antibodies.

Authors:  Venkata R Doppalapudi; Jie Huang; Dingguo Liu; Ping Jin; Bin Liu; Lingna Li; Joel Desharnais; Crystal Hagen; Nancy J Levin; Michael J Shields; Michelle Parish; Robert E Murphy; Joselyn Del Rosario; Bryan D Oates; Jing-Yu Lai; Marla J Matin; Zemeda Ainekulu; Abhijit Bhat; Curt W Bradshaw; Gary Woodnutt; Richard A Lerner; Rodney W Lappe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

6.  Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma.

Authors:  Ping Guo; Yorihisa Imanishi; Frank C Cackowski; Michael J Jarzynka; Huo-Quan Tao; Ryo Nishikawa; Takanori Hirose; Bo Hu; Shi-Yuan Cheng
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

Authors:  V Goede; O Coutelle; J Neuneier; A Reinacher-Schick; R Schnell; T C Koslowsky; M R Weihrauch; B Cremer; H Kashkar; M Odenthal; H G Augustin; W Schmiegel; M Hallek; U T Hacker
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

8.  Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway.

Authors:  Yorihisha Imanishi; Bo Hu; Michael J Jarzynka; Ping Guo; Esther Elishaev; Ifat Bar-Joseph; Shi-Yuan Cheng
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

9.  Angiopoietin-2 expression is correlated with angiogenesis and overall survival in oral squamous cell carcinoma.

Authors:  Chao Li; Chang-jin Sun; Jin-chuan Fan; Ning Geng; Chun-hua Li; Jian Liao; Kun Mi; Gui-quan Zhu; Hong Ma; Yu-feng Song; Ya-ling Tang; Yu Chen
Journal:  Med Oncol       Date:  2013-05-07       Impact factor: 3.064

10.  Expression of angiopoietin-2 and vascular endothelial growth factor receptor-3 correlates with lymphangiogenesis and angiogenesis and affects survival of oral squamous cell carcinoma.

Authors:  Chao Li; Jinchuan Fan; Xicheng Song; Bing Zhang; Yu Chen; Chunhua Li; Kun Mi; Hong Ma; Yufeng Song; Xiaofeng Tao; Guojun Li
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.